Default company panoramic image


Creoptix develops and markets analytical instruments for drug discovery: highest-sensitivity at low complex components.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location 8810 Wädenswil, ZH, Switzerland
  • Currency CHF
  • Founded March 2009
  • Employees 2
  • Website

Company Summary

Drugs work by binding to their drug target. To analyse this binding is therefore key for the pharmaceutical industry. The sensitivity of current methods is however often limiting. Based on proprietary and patented disruptive technology, Creoptix has developed its first product, QUBE, a system of instrument and disposables achieving highest-sensitivity at low complex components. Qube will be launched by end of 2013.


  • Default avatar
    Kaspar Cottier
    Managing Partner and Founder

    Dipl. Ing. Microtechnology EPFL, PhD at CSEM, CAS BA FHSG / 2005-2010: Sperian Welding Protection, Wattwil (3y as Dir. Operations) / Founder, since 2010 full time at Creoptix (R&D, IP, Operations)

  • Default avatar
    Matyas Vegh
    Managing Partner

    Master in Biology at Biocentre UniBS, PhD at UniZH, EMBA UniSG / 2002-2010: The Genetics Company, Schlieren (since 2007 as CEO) / 2010-2012: Managing Partner at Nextech Invest, Zurich / Since end 2012 full time at Creoptix (Finance, M&S, BD)